Evidence map›Paper›PMID 32488949›Full record

ArticleNeuropathology : official journal of the Japanese Society of Neuropathology2020

Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains.

Yoichi Chiba, Yasunori Sugiyama, Nozomu Nishi, Wakako Nonaka, Ryuta Murakami, Masaki Ueno

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropathology : official journal of the Japanese Society of Neuropathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 50 citations in OpenAlex.

  1. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Brain development and bioenergetic changes.Neurobiology of disease · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yoichi ChibaDepartment of Pathology and Host Defense, Kagawa University, Kagawa, Japan.
Yasunori SugiyamaDepartment of Life Sciences, Kagawa University, Kagawa, Japan.
Nozomu NishiLife Science Research Center, Kagawa University, Kagawa, Japan.
Wakako NonakaDepartment of Supportive and Promotive Medicine of the Municipal Hospital, Kagawa University, Kagawa, Japan.
Ryuta MurakamiDepartment of Pathology and Host Defense, Kagawa University, Kagawa, Japan.
Masaki UenoDepartment of Pathology and Host Defense, Kagawa University, Kagawa, Japan.ORCID https://orcid.org/0000-0002-6592-3573
Kagawa University · JP

Funding

Japan Society for the Promotion of Science 17K08788Japan Society for the Promotion of Science 19K07508
6 · The paper itself

Abstract

Diabetes mellitus (DM) is now recognized as one of the risk factors for Alzheimer's disease (AD), and the disease-modifying effects of anti-diabetic drugs on AD have recently been attracting great attention. Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a new class of anti-diabetic drugs targeting the SGLT2/solute carrier family 5 member 2 (SLC5A2) protein, which is known to localize exclusively in the brush border membrane of early proximal tubules in the kidney. However, recent data suggest that it is also expressed in other tissues. In the present study, we investigated the expression of SGLT2/SLC5A2 in human and mouse brains. Immunohistochemical staining of paraffin sections from autopsied human brains and C3H/He mouse brains revealed granular cytoplasmic immunoreactivity in choroid plexus epithelial cells and ependymal cells. Immunoblot analysis of the membrane fraction of mouse choroid plexus showed distinct immunoreactive bands at 70 and 26 kDa. Band patterns around 70 kDa in the membrane fraction of the choroid plexus were different from those in the kidney. Reverse transcription-polymerase chain reaction analysis confirmed the expression of Slc5a2 mRNA in the mouse choroid plexus. Our results provide in vivo evidence that SGLT2/SLC5A2 is expressed in cells facing the cerebrospinal fluid, in addition to early proximal tubular epithelial cells. These findings suggest that SGLT2 inhibitors may have another site of action in the brain. The effects of SGLT2 inhibitors on brain function and AD progression merit further investigation to develop better treatment options for DM patients.

Indexed as

AdultAgedAnimalsBrainChoroid PlexusEpithelial CellsFemaleHumansKidneyMaleMiceMice, Inbred C3HMiddle AgedSodium-Glucose Transporter 2SLC5A2 protein, humanSlc5a2 protein, mouseSodium-Glucose Transporter 2central nervous systemdiabetes mellitusimmunolabelingmRNASLC5A2

Identifiers

PMID32488949
PMCPMC7587001
OpenAlexW3030772015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.